Novel strategies to combat bacterial virulence.
OBJECTIVE
Incidences of antimicrobial-resistant infections have increased dramatically over the past several decades and are associated with adverse patient outcomes. Alternative approaches to combat infection are critical and have led to the development of more specific drugs targeted at particular bacterial virulence systems or essential regulatory pathways. The purpose of this review is to highlight the recent developments in antibacterial therapy and the novel approaches toward increasing our therapeutic armory against bacterial infection.


RESULTS
Although classic antibiotic development is not occurring rapidly, alternative therapeutics that target specific bacterial virulence systems are progressing from the discovery stage through the Food and Drug Administration approval process. Here we review novel antibodies that target specific virulence systems as well as a variety of newly discovered small molecules that block bacterial attachment, communication systems (quorum sensing) or important regulatory processes associated with virulence gene expression.


CONCLUSIONS
The success of novel therapeutics could significantly change clinical practice. Furthermore, the complications of collateral damage due to antibiotic administration, for example, suprainfections or decreased host immunity due to loss of synergistic bacterial communities, may be minimized using therapeutics that specifically target pathogenic behavior.
Lynch
Susan V
SV
Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California 94143, USA. lynchs@anesthesia.ucsf.edu
Wiener-Kronish
Jeanine P
JP
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D003422:Critical Care; D024881:Drug Resistance, Bacterial / Q000187:drug effects / Q000235:genetics; D006801:Humans; D053038:Quorum Sensing / Q000187:drug effects; D014774:Virulence
D000900:Anti-Bacterial Agents
Curr Opin Microbiol. 2000 Feb;3(1):65-72
10679419
Nature. 2006 Dec 21;444(7122):1022-3
17183309
Microbiology (Reading). 2001 Dec;147(Pt 12):3249-62
11739757
Microbiology (Reading). 2005 Dec;151(Pt 12):3873-3880
16339933
J Clin Microbiol. 2007 Jun;45(6):1954-62
17409203
Burns. 2005 Mar;31(2):153-8
15683685
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20529-33
18077362
Microbiology (Reading). 2001 Sep;147(Pt 9):2517-2528
11535791
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2771-6
12601166
Biochim Biophys Acta. 2006 Apr;1760(4):527-37
16564136
Chembiochem. 2001 Dec 3;2(12):915-8
11948880
J Clin Invest. 1999 Sep;104(6):743-50
10491409
Nature. 2006 Dec 21;444(7122):1027-31
17183312
Am J Health Syst Pharm. 2008 Apr 15;65(8):705-15
18387898
Infect Immun. 2000 May;68(5):2916-24
10768989
J Clin Invest. 2007 Apr;117(4):877-88
17364024
Nat Med. 1999 Apr;5(4):392-8
10202927
EMBO J. 2000 Jun 15;19(12):2803-12
10856226
Mol Pharmacol. 2008 May;73(5):1578-86
18314496
Nat Struct Mol Biol. 2004 Jan;11(1):60-6
14718924
J Infect Dis. 2001 Jun 15;183(12):1767-74
11372029
J Infect Dis. 2002 Jul 1;186(1):64-73
12089663
J Antimicrob Chemother. 2004 Jun;53(6):1054-61
15117922
Mol Microbiol. 1997 Mar;23(5):861-7
9076724
Nature. 2002 Jul 25;418(6896):386
12140548
Eur Respir J. 2007 May;29(5):965-8
17301098
Nat Struct Mol Biol. 2004 Jan;11(1):67-72
14718925
Org Biomol Chem. 2007 Jun 21;5(12):1827-34
17551629
Mol Microbiol. 2007 Sep;65(5):1311-20
17697254
Vaccine. 2008 Mar 20;26(13):1616-25
18304706
Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11
17485504
Mol Microbiol. 1999 Sep;33(6):1254-66
10510239
Infect Immun. 1980 May;28(2):546-56
6772562
PLoS Pathog. 2007 Dec;3(12):e196
18159943
J Immune Based Ther Vaccines. 2003 Aug 13;1(1):2
12943554
PLoS Med. 2007 Dec;4(12):e349
18092887
Infect Immun. 1997 Oct;65(10):4199-206
9317027
Infect Immun. 1987 Feb;55(2):472-6
3542836
EMBO J. 2003 Aug 1;22(15):3803-15
12881415
J Bacteriol. 2007 Mar;189(6):2203-9
17209027
J Med Microbiol. 2006 Jun;55(Pt 6):669-675
16687583
Anaerobe. 2005 Oct;11(5):247-51
16701579
Mol Microbiol. 1996 Mar;19(5):1107-16
8830267
Microbiology (Reading). 2007 Jul;153(Pt 7):2363-2372
17600080
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
16033867
J Bacteriol. 2007 Jul;189(14):5383-6
17496081
Mol Microbiol. 1997 Aug;25(3):547-57
9302017
Crit Care Med. 2004 Nov;32(11):2293-9
15640644
Adv Drug Deliv Rev. 2002 Dec 5;54(11):1425-43
12458153
Dev Cell. 2002 Oct;3(4):593-603
12408810
J Nutr. 2005 Oct;135(10):2445-8
16177210
Science. 2005 Oct 28;310(5748):670-4
16223984
Can J Microbiol. 1996 May;42(5):479-86
8640607
Infect Immun. 2003 Jul;71(7):3673-81
12819047
Mol Microbiol. 2007 May;64(4):968-83
17501921
Environ Microbiol. 2002 Jan;4(1):18-28
11966822
Mol Microbiol. 2006 Aug;61(3):782-94
16803594
Cell Microbiol. 2007 Sep;9(9):2230-41
17490405
Infect Immun. 2007 Jan;75(1):52-60
17074856
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17897-902
17098869
Microbiology (Reading). 2005 May;151(Pt 5):1325-1340
15870443
Science. 2005 Jun 10;308(5728):1635-8
15831718
Infect Immun. 2005 May;73(5):3104-14
15845518
J Med Chem. 2005 Feb 24;48(4):935-45
15715464